- Home
- CFR vs ROIV Comparison
CFR vs ROIV Comparison
Compare CFR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | ROIV |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 721 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 28.7B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CFR | ROIV |
|---|---|---|
| Price | $157.59 | $35.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $142.31 | $28.94 |
| AVG Volume (30 Days) | 432.2K | ★ 8.7M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | ★ 5.35 | N/A |
| Revenue | ★ $2,235,244,000.00 | $8,260,000.00 |
| Revenue This Year | $9.72 | N/A |
| Revenue Next Year | $4.70 | $744.61 |
| P/E Ratio | $29.20 | ★ N/A |
| Revenue Growth | ★ 8.31 | N/A |
| 52 Week Low | $119.00 | $14.86 |
| 52 Week High | $170.80 | $42.50 |
Technical Indicators
Market Signals| Indicator | CFR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 40.85 |
| Support Level | $157.64 | $33.15 |
| Resistance Level | $165.28 | $37.12 |
| Average True Range (ATR) | 2.95 | 1.45 |
| MACD | -0.56 | -0.52 |
| Stochastic Oscillator | 32.42 | 4.15 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $54 billion in assets (as of June 2026), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based banking approach that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through targeted branch openings rather than acquisitions. The bank's sweet spot is small to medium-sized Texas-based commercial clients.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.